Vancomycin with Taper/Pulse — Competitive Intelligence Brief

Vancomycin with Taper/Pulse (Vancomycin with Taper/Pulse) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycopeptide antibiotic. Area: Infectious Disease.

marketed Glycopeptide antibiotic Bacterial peptidoglycan (D-Ala-D-Ala) Infectious Disease Small molecule

Target snapshot

Vancomycin with Taper/Pulse (Vancomycin with Taper/Pulse) — VA Office of Research and Development. Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, and a taper/pulse dosing regimen modulates exposure to reduce toxicity while maintaining efficacy.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vancomycin with Taper/Pulse TARGET	Vancomycin with Taper/Pulse	VA Office of Research and Development	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Prophylactic Vancomycin	Prophylactic Vancomycin	Memorial Sloan Kettering Cancer Center	phase 3	Glycopeptide antibiotic	Bacterial peptidoglycan D-Ala-D-Ala precursors
Dalbavancin via Intravenous Administration	Dalbavancin via Intravenous Administration	University of Colorado, Denver	marketed	Lipoglycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursors
Vancomycin - model-based dosing regimen	Vancomycin - model-based dosing regimen	Murdoch Childrens Research Institute	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Vancomycin IV	Vancomycin IV	Debiopharm International SA	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Vancomycin antimicrobial-lock solution	Vancomycin antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Glycopeptide antibiotic	Bacterial cell wall (peptidoglycan precursors)
Vancomycin II	Vancomycin II	Wake Forest University Health Sciences	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycopeptide antibiotic class)

1. Clinica Universidad de Navarra, Universidad de Navarra · 2 drugs in this class
2. Memorial Sloan Kettering Cancer Center · 2 drugs in this class
3. Wake Forest University Health Sciences · 2 drugs in this class
4. VA Office of Research and Development · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Murdoch Childrens Research Institute · 1 drug in this class
7. OrthoCarolina Research Institute, Inc. · 1 drug in this class
8. University of Colorado, Denver · 1 drug in this class
9. University of Maryland, Baltimore · 1 drug in this class
10. Debiopharm International SA · 1 drug in this class